As litigation against some of the world’s foremost drugmakers finally enters the courtroom, some companies have already settled a number…
McAlinden Research PartnersJune 25, 2019
At first glance, first quarter earnings for the pharmaceutical sector appear to be largely positive, with only a few nuggets…
McAlinden Research PartnersMay 1, 2019
The world is seeing an escalation of obesity due to energy-sparing technology, sugary drinks, packaged or fast food, and the…
McAlinden Research PartnersMarch 25, 2019
As the supply of doctors is projected to become increasingly insufficient over the next decade and beyond, healthcare providers will…
McAlinden Research PartnersMarch 20, 2019
Startups are experimenting with the gene-editing technology CRISPR to make lab-grown meat a commercially viable reality. Meanwhile, the first commercially…
McAlinden Research PartnersMarch 18, 2019
Investors seeking a more defensive positioning have rushed into health care stocks in recent months, as hype about the aging…
McAlinden Research PartnersFebruary 4, 2019
Just as Uber and Lyft connect riders to drivers via technology, so too are telehealth companies connecting patients and doctors…
McAlinden Research PartnersJanuary 14, 2019
“CRISPR babies” have been on everyone’s lips since news broke last week that Chinese scientists claimed they had produced the…
McAlinden Research PartnersDecember 4, 2018
The Trump Administration may finally be taking serious action against the pharmaceutical industry in a bid to cut down heavily…
McAlinden Research PartnersOctober 30, 2018
